Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Victoza is Novo Nordisk’s once-daily injectable GLP-1 agonist and made around $3.6 billion in sales last year, making it the top-selling drug in the category.

Let's continue. Novo Nordisk's semaglutide franchise consists of Ozempic, Rybelsus, and Victoza, whose sales totaled about DKK 40.77 billion in the last three months of 2024, up 15.6% quarter-on ...

Novo Nordisk’s strong intangible assets in diabetes ... and biosimilar insulins have weighed on category pricing since 2017. Novo’s Victoza and Ozempic have made GLP-1 a key part of the ...

Novo Nordisk is making the case for its diabetes ... Trulicity has been stealing market share from Novo's GLP-1 Victoza (liraglutide). The first trial, PIONEER 4, set the new drug against Novo ...

Victoza, produced by Novo Nordisk, holds FDA approval for regulating blood sugar levels among individuals diagnosed with type ...

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

REUTERS Other GLP-1 medications include Ozempic, Wegovy, Victoza, Saxenda, all made by Novo Nordisk. Fetterman noted that GLP ...

Finally, a 2021 study funded by Novo Nordisk (the manufacturer of Victoza and Saxenda) found that combining liraglutide and exercise led to more weight loss than either treatment alone.